Shots:
- Biocytogen has entered into a global collaboration with Whitehawk Therapeutics to develop bispecific antibody-drug conjugates (BsADCs)
- Biocytogen will provide ~5 bispecific antibodies from its RenLite platform & Whitehawk will evaluate these in combination with its ADC linker-payload technologies, with Whitehawk holding the option to advance resulting BsADC candidates
- Biocytogen will receive an upfront payment, development, regulatory, & commercial milestones, plus low single-digit royalties, while Whitehawk may obtain global rights & full program control upon exercising its option to advance BsADC candidates
Ref: Businesswire | Image: Biocytogen & Whitehawk | Press Release
Related News: Biocytogen and Sihuan Pharmaceutical Partner to Discover Novel Therapeutics in Multiple Indications
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
